FDA Awards Fast-Track Voucher for Rare Kids' Blood Disorder Drug
Published Date: 2/23/2026
Notice
Summary
The FDA just gave a special fast-track prize called a Priority Review Voucher to Fondazione Telethon ETS for their rare disease treatment, WASKYRA, approved in December 2025. This medicine helps kids and adults with Wiskott-Aldrich Syndrome who need a stem cell transplant but can’t find a perfect donor. This voucher speeds up future drug reviews and can be sold, saving time and money for drug developers.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
WASKYRA Approved for WAS Patients
WASKYRA (etuvetidigene autotemcel) was approved on December 9, 2025, for pediatric patients aged 6 months and older and adults with Wiskott-Aldrich Syndrome who have a mutation in the WAS gene and for whom hematopoietic stem cell transplantation (HSCT) is appropriate and no suitable HLA‑matched related stem cell donor is available. If you are in that patient group, this approval makes the treatment an approved option.
FDA Issues Rare Disease Priority Voucher
The FDA issued a Priority Review Voucher to Fondazione Telethon ETS for WASKYRA after its approval on December 9, 2025. The notice says this voucher speeds up future drug reviews and can be sold, which can save time and money for drug developers.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-03492, Petition for Exemption; Summary of Petition Received; Morningside University
Morningside University has asked the FAA for a special exemption from some aviation rules. This could affect students and staff involved in their aviation programs by changing how certain regulations apply. People have until March 16, 2026, to share their thoughts, and no extra costs or delays are expected right now.
Next: 2026-03495, Determination That Klonopin (Clonazepam) Tablets, 0.125 Milligrams and 0.25 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that Klonopin tablets in 0.125 mg and 0.25 mg strengths were not taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their versions of these Klonopin tablets, as long as they meet all other rules. Patients and pharmacies could see more affordable options soon, with no safety worries holding things back.